MCID: FLL022
MIFTS: 16

Fallopian Tube Clear Cell Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Clear Cell Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Clear Cell Adenocarcinoma:

Name: Fallopian Tube Clear Cell Adenocarcinoma 12 74
Clear Cell Carcinoma of the Fallopian Tube 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5301
NCIt 51 C6280
UMLS 74 C1333591

Summaries for Fallopian Tube Clear Cell Adenocarcinoma

Disease Ontology : 12 A fallopian tube adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Fallopian Tube Clear Cell Adenocarcinoma, also known as clear cell carcinoma of the fallopian tube, is related to adenocarcinoma and clear cell adenocarcinoma. The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include endothelial.

Related Diseases for Fallopian Tube Clear Cell Adenocarcinoma

Diseases related to Fallopian Tube Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.2
2 clear cell adenocarcinoma 10.2

Symptoms & Phenotypes for Fallopian Tube Clear Cell Adenocarcinoma

Drugs & Therapeutics for Fallopian Tube Clear Cell Adenocarcinoma

Drugs for Fallopian Tube Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
4
Olaparib Approved Phase 2, Phase 3,Phase 3,Phase 1 763113-22-0 23725625
5
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
6
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
7
Gemcitabine Approved Phase 2, Phase 3,Phase 3 95058-81-4 60750
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
10
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
11
Maleic acid Experimental, Investigational Phase 2, Phase 3,Phase 3 110-17-8, 110-16-7 444972
12
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
13
Cediranib Investigational Phase 2, Phase 3,Phase 3 288383-20-0 9933475
14 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
15 Immunoglobulins Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
17 Antimitotic Agents Phase 3,Phase 2,Phase 1
18 Immunoglobulin G Phase 3,Phase 2,Phase 1
19 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
20 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
21 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
24 Antibodies Phase 3,Phase 2,Phase 1
25 Mitogens Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Micronutrients Phase 3,Not Applicable
29 Carotenoids Phase 3
30 Trace Elements Phase 3,Not Applicable
31 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
32 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
33 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
34 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
35 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3
36 topoisomerase I inhibitors Phase 2, Phase 3
37 taxane Phase 3
38 Antimetabolites Phase 3
39 Antimetabolites, Antineoplastic Phase 3
40 Immunosuppressive Agents Phase 3,Phase 2
41 Antiviral Agents Phase 3
42 Anti-Infective Agents Phase 3
43
Pembrolizumab Approved Phase 2 1374853-91-4
44
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
45
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
46
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
47
Entinostat Investigational Phase 1, Phase 2 209783-80-2
48 Antirheumatic Agents Phase 2
49 Antineoplastic Agents, Alkylating Phase 2
50 Alkylating Agents Phase 2

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
3 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
4 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
5 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
6 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
7 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
8 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02315430 Phase 2 Cabozantinib S-malate
9 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
10 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
11 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02923739 Phase 2 Paclitaxel
12 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
13 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
14 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Not yet recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
15 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
16 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
17 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
18 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
19 Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy Active, not recruiting NCT02111941 Not Applicable
20 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Fallopian Tube Clear Cell Adenocarcinoma

Genetic Tests for Fallopian Tube Clear Cell Adenocarcinoma

Anatomical Context for Fallopian Tube Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Clear Cell Adenocarcinoma:

42
Endothelial

Publications for Fallopian Tube Clear Cell Adenocarcinoma

Articles related to Fallopian Tube Clear Cell Adenocarcinoma:

# Title Authors Year
1
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )
2015

Variations for Fallopian Tube Clear Cell Adenocarcinoma

Expression for Fallopian Tube Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Clear Cell Adenocarcinoma.

Pathways for Fallopian Tube Clear Cell Adenocarcinoma

GO Terms for Fallopian Tube Clear Cell Adenocarcinoma

Sources for Fallopian Tube Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....